Strategic partnerships Certest Biotec actively pursues collaborations with pharma and diagnostics players as shown by partnerships with Almirall and Pro-Lab Diagnostics, plus a broad ecosystem involving Circio and Emervax. This indicates strong open channels for co-development, licensing, and distribution agreements that sales teams can leverage to expand market reach.

Integrated solutions The company operates four divisions—Raw Materials, Immunodiagnostics, VIASURE molecular diagnostics, and Pharma—offering end-to-end capabilities from components to finished diagnostic and therapeutic platforms. This presents opportunities to cross-sell bundled solutions to labs seeking turnkey IVD development, manufacturing, and regulatory-ready products.

RNA and vaccines focus Certest Pharma emphasizes RNA, delivery, and vaccines, aligning with current biotechnology demand for RNA-based therapies and vaccine platforms. Sales opportunities exist with labs and biotechs pursuing RNA-enabled therapeutics, delivery systems, and related manufacturing services.

Global conference visibility Active participation in major conferences such as the European Society for Clinical Virology signals a commitment to visibility among clinical virology stakeholders and potential customers. Leverage conference appearances to initiate relationships, feature collaboration capabilities, and gather qualification signals from attending labs.

Scale-ready capabilities With a workforce over 300 and capabilities in protein expression, monoclonal antibodies, primers and probes, and rapid diagnostics, Certest positions itself as a scalable supplier for custom development and manufacturing. Target mid to large CROs and diagnostic labs seeking reliable capacity, regulatory-compliant production, and speed to market.